Literature DB >> 26835356

Energy metabolism in neuroblastoma and Wilms tumor.

Sepideh Aminzadeh1, Silvia Vidali1, Wolfgang Sperl1, Barbara Kofler1, René G Feichtinger1.   

Abstract

To support high proliferation, the majority of cancer cells undergo fundamental metabolic changes such as increasing their glucose uptake and shifting to glycolysis for ATP production at the expense of far more efficient mitochondrial energy production by oxidative phosphorylation (OXPHOS), which at first glance is a paradox. This phenomenon is known as the Warburg effect. However, enhanced glycolysis is necessary to provide building blocks for anabolic growth. Apart from the generation of ATP, intermediates of glycolysis serve as precursors for a variety of biosynthetic pathways essential for cell proliferation. In the last 10-15 years the field of tumor metabolism has experienced an enormous boom in interest. It is now well established that tumor suppressor genes and oncogenes often play a central role in the regulation of cellular metabolism. Therefore, they significantly contribute to the manifestation of the Warburg effect. While much attention has focused on adult solid tumors, so far there has been comparatively little effort directed at elucidation of the mechanism responsible for the Warburg effect in childhood cancers. In this review we focus on metabolic pathways in neuroblastoma (NB) and Wilms tumor (WT), the two most frequent solid tumors in children. Both tumor types show alterations of the OXPHOS system and glycolytic features. Chromosomal alterations and activation of oncogenes like MYC or inactivation of tumor suppressor genes like TP53 can in part explain the changes of energy metabolism in these cancers. The strict dependence of cancer cells on glucose metabolism is a fairly common feature among otherwise biologically diverse types of cancer. Therefore, inhibition of glycolysis or starvation of cancer cells through glucose deprivation via a high-fat low-carbohydrate diet may be a promising avenue for future adjuvant therapeutic strategies.

Entities:  

Keywords:  Cancer metabolism; Wilms tumor (WT); mitochondria; neuroblastoma (NB); oxidative phosphorylation (OXPHOS)

Year:  2015        PMID: 26835356      PMCID: PMC4729069          DOI: 10.3978/j.issn.2224-4336.2015.01.04

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


  121 in total

1.  BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.

Authors:  J Hagenbuchner; A V Kuznetsov; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

2.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

3.  Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.

Authors:  J M Maris; M J Weiss; C Guo; R B Gerbing; D O Stram; P S White; M D Hogarty; E P Sulman; P M Thompson; J N Lukens; K K Matthay; R C Seeger; G M Brodeur
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

Review 4.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

5.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

Review 6.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

Review 7.  The interplay between MYC and HIF in cancer.

Authors:  Chi V Dang; Jung-whan Kim; Ping Gao; Jason Yustein
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

8.  Progressive tumor features accompany epithelial-mesenchymal transition induced in mitochondrial DNA-depleted cells.

Authors:  Akihiro Naito; Cody C Cook; Takatsugu Mizumachi; Mian Wang; Cheng-Hui Xie; Teresa T Evans; Thomas Kelly; Masahiro Higuchi
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

9.  No evidence for involvement of SDHD in neuroblastoma pathogenesis.

Authors:  Katleen De Preter; Jo Vandesompele; Jasmien Hoebeeck; Caroline Vandenbroecke; Jöel Smet; Annick Nuyts; Geneviève Laureys; Valérie Combaret; Nadine Van Roy; Frank Roels; Rudy Van Coster; Marleen Praet; Anne De Paepe; Frank Speleman
Journal:  BMC Cancer       Date:  2004-08-24       Impact factor: 4.430

10.  Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours.

Authors:  H Carén; S Fransson; K Ejeskär; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

View more
  33 in total

1.  A Pilot Study Into the Use of FDG-mNP as an Alternative Approach in Neuroblastoma Cell Hyperthermia.

Authors:  Mahendran Subramanian; Gillian Pearce; Ozge Kozgus Guldu; Volkan Tekin; Arkadiusz Miaskowski; Omer Aras; Perihan Unak
Journal:  IEEE Trans Nanobioscience       Date:  2016-09       Impact factor: 2.935

Review 2.  Metabolic requirements of the nephron.

Authors:  Kasey Cargill; Sunder Sims-Lucas
Journal:  Pediatr Nephrol       Date:  2018-12-15       Impact factor: 3.714

3.  Macrophages and monocytes mediated activation of oxidative phosphorylation implicated the prognosis and clinical therapeutic strategy of Wilms tumour.

Authors:  Jialin Meng; Yonghao Chen; Xiaofan Lu; Qintao Ge; Feixiang Yang; Suwen Bai; Chaozhao Liang; Juan Du
Journal:  Comput Struct Biotechnol J       Date:  2022-06-27       Impact factor: 6.155

4.  Novel piRNA MW557525 regulates the growth of Piwil2-iCSCs and maintains their stem cell pluripotency.

Authors:  Liming Jin; Zhaoxia Zhang; Zhang Wang; Xiaojun Tan; Zhaoying Wang; Lianju Shen; Chunlan Long; Guanghui Wei; Dawei He
Journal:  Mol Biol Rep       Date:  2022-04-11       Impact factor: 2.742

5.  Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma.

Authors:  Xiao Chang; Marina Bakay; Yichuan Liu; Joseph Glessner; Komal S Rathi; Cuiping Hou; Huiqi Qu; Zalman Vaksman; Kenny Nguyen; Patrick M A Sleiman; Sharon J Diskin; John M Maris; Hakon Hakonarson
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

Review 6.  Targeting metabolic dependencies in pediatric cancer.

Authors:  Sameer H Issaq; Christine M Heske
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

7.  Assessment of Mitochondrial Cell Metabolism by Respiratory Chain Electron Flow Assays.

Authors:  Flavia Radogna; Déborah Gérard; Mario Dicato; Marc Diederich
Journal:  Methods Mol Biol       Date:  2021

8.  Functional and Proteomic Investigations Reveal Major Royal Jelly Protein 1 Associated with Anti-hypertension Activity in Mouse Vascular Smooth Muscle Cells.

Authors:  Pei Fan; Bin Han; Mao Feng; Yu Fang; Lan Zhang; Han Hu; Yue Hao; Yuping Qi; Xiaozhen Zhang; Jianke Li
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

9.  Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.

Authors:  Raphael Johannes Morscher; Sepideh Aminzadeh-Gohari; Cornelia Hauser-Kronberger; René Günther Feichtinger; Wolfgang Sperl; Barbara Kofler
Journal:  Oncotarget       Date:  2016-03-29

10.  LINC00839 Regulates Proliferation, Migration, Invasion, Apoptosis and Glycolysis in Neuroblastoma Cells Through miR-338-3p/GLUT1 Axis.

Authors:  Lixia Yang; Liangyan Pei; Jilong Yi
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-21       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.